Congestive heart failure in patients treated with doxorubicin

By S. Swain, F. Whaley, M. Ewer. Cancer, 2003

1,739 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Oncology

View Paper: https://www.semanticscholar.org/paper/d10003948dd79ad520aecd51ef8b874868500cbd

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. J. Herrmann
2. Jose Luis Zamorano
3. D. Lenihan
4. P. Lancellotti
5. R. Russell
6. M. Volkova

In Oncology

1. W. Gu
2. J. Herrmann

Citations in the corpus

• Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. (2009, background): “retrospective review of 3 trials, the incidence of HF was ound to be 26% with cumulative doses of 550 mg/m(2) (7).”
• Ferroptosis as a target for protection against cardiomyopathy (2019, methodology): “Based on an analysis of three separate phase III clinical trials, an estimated 26% of cancer patients develop DOX-related congestive heart failure following a cumulative dose of 550 mg/m(2) (9); moreover, more than half of all elderly patients with lymphoma and survivors of childhood cancer who were”
• Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. (2010, background): “Echocardiography examinations, however, although useful for identifying and monitoring patients with asymptomatic cardiac dysfunction, does not provide any predictive information.(7,30,31) We have previously demonstrated that TNI , soon after highdose chemotherapy (mainly based on anthracycline-cont”
• Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment (2011, background): “1% of patients had evidence of congestive heart failure or a significant decline in left ventricular function and confirmed the cumulative dose-dependence of doxorubicin cardiotoxicity [9].”
• Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations (2020, background): “Patients with reduced LVEF (<50%) at baseline are highrisk and should be treated with anthracyclines cautiously due to the risk of recurrent or progressive irreversible cardiotoxicity with additional cumulative anthracycline dosing.(106,107,109) If there are acceptable alternative anticancer agents ”